Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | NT5E | P21589 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | PNP | P00491 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.40 |
| ▸ | CHKA | P35790 | 1/20 | 0.40 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21614181 | 1.00 | AHCY (0.54) | AHCYLMNANT5EHIF1AADORA3 | |
| SCHEMBL31652941 | 1.00 | AHCY (0.54) | AHCYLMNANT5EHIF1AADORA3 | |
| SCHEMBL30689530 | 1.00 | AHCY (0.54) | AHCYLMNANT5EHIF1AADORA3 | |
| SCHEMBL24195283 | 1.00 | AHCY (0.54) | AHCYLMNANT5EHIF1AADORA3 | |
| SCHEMBL9548611 | 0.89 | AHCY (0.53) | AHCYLMNANT5EADORA3ADORA2A | |
| SCHEMBL9548618 | 0.89 | AHCY (0.53) | AHCYLMNANT5EADORA3ADORA2A | |
| SCHEMBL25396825 | 0.88 | AHCY (0.55) | AHCYLMNANT5EHIF1AADORA3 | |
| SCHEMBL25865564 | 0.88 | AHCY (0.56) | AHCYLMNANT5EHIF1AADORA3 | |
| SCHEMBL23966231 | 0.87 | PDE4D (0.61) | LMNANT5EADORA3ADORA2AADORA2B | |
| SCHEMBL12736902 | 0.87 | PDE4D (0.61) | LMNANT5EADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-12037623-B2 | Enzymatic synthesis of 4′-ethynyl nucleoside analogs | Merck, Sharp & Dohme LLC (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230374486-A1 | ENGINEERED PHOSPHOPENTOMUTASE VARIANT ENZYMES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2023-11-23 | — | — | US | disclosed |
| US-11795445-B2 | Engineered phosphopentomutase variant enzymes | CODEXIS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11793827-B2 | Adenosine derivative and pharmaceutical composition comprising the same | BRII BIOSCIENCES, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| WO-2023192499-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | PRIMEFOUR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023178128-A1 | METHODS OF TREATING MEDICAL CONDITIONS USING ISLATRAVIR OR A RELATED COMPOUND | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230174534-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2023-06-08 | — | — | US | disclosed |
| US-20230151049-A1 | Compounds Useful in HIV Therapy | VIIV HEALTHCARE COMPANY (US) | 2023-05-18 | — | — | US | disclosed |
| US-11034948-B2 | Engineered phosphopentomutase variant enzymes | CODEXIS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210154221-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2021-05-27 | — | — | US | disclosed |
| US-10953029-B2 | 4′-Substituted nucleoside reverse transcriptase inhibitors and preparations thereof | MERCK SHARP & DOHME CORP. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20210060051-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | EMORY UNIVERSITY | 2021-03-04 | — | — | US | disclosed |
| WO-2021030306-A1 | DRUG DELIVERY SYSTEM FOR THE DELIVERY OF ANTIVIRAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021021717-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | BRII BIOSCIENCES, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| WO-2021003129-A2 | ENGINEERED ACETATE KINASE VARIANT ENZYMES | CODEXIS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2020263660-A1 | PROCESS FOR THE PREPARATION OF 2-FLUOROADENINE | MERCK SHARP & DOHME CORP. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020044257-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-03-05 | — | — | WO | disclosed |
| US-20190022115-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154221-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | HPRT1, SAMHD1, DUT | AHCY 519/4885LMNA 2288/4885NT5E 89/4885 |
| US-12037623-B2 | Enzymatic synthesis of 4′-ethynyl nucleoside analogs | GALE, ENGASE, RNGTT | AHCY 499/4885LMNA 2519/4885NT5E 75/4885 |
| US-20230174534-A1 | COMPOUNDS USEFUL IN HIV THERAPY | CCR5, CD4, LSS | AHCY 1161/4885LMNA 2608/4885NT5E 1408/4885 |
| US-11793827-B2 | Adenosine derivative and pharmaceutical composition comprising the same | ADAR, ADA, ADORA2A | AHCY 159/4885LMNA 2057/4885NT5E 58/4885 |
| US-20210060051-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | NOX1, NOX3, NOX4 | AHCY 459/4885LMNA 4207/4885NT5E 141/4885 |
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | TYMP, TYMS, DCTD | AHCY 248/4885LMNA 3687/4885NT5E 159/4885 |
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | UNG, OGG1, NTPCR | AHCY 201/4885LMNA 1053/4885NT5E 83/4885 |
| US-20230151049-A1 | Compounds Useful in HIV Therapy | CCR5, CD4, NPC1 | AHCY 1195/4885LMNA 2405/4885NT5E 1724/4885 |
| US-20190022115-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | HPRT1, DUT, SAMHD1 | AHCY 604/4885LMNA 2165/4885NT5E 122/4885 |
| US-10953029-B2 | 4′-Substituted nucleoside reverse transcriptase inhibitors and preparations thereof | DUT, HPRT1, SAMHD1 | AHCY 626/4885LMNA 2109/4885NT5E 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.